ICON is Shortlisted for Two Vaccine Industry Excellence Awards


Cast your votes today!

ICON shortlisted for Best CRO and PMG Research nominated for Best Clinical Trial Site/Network

Dublin, Ireland, 11th February, 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that is has been shortlisted for two awards in the 2016 Vaccine Industry Excellence Awards. The VIE Awards honour organisations and individuals who have demonstrated an unparalleled ability to succeed and to continually set standards of excellence and advocacy in vaccine development over the previous 12 months.

ICON has been shortlisted in the Best CRO category, while PMG Research, which ICON acquired in December 2015, has been shortlisted for the Best Clinical Trial Site or Network Category.

ICON has been shortlisted as Best CRO according to the following criteria:

  • The range of services provided in niche and core therapeutic areas
  • Methods of performance improvement or introduction of new services
  • Attention to and quality of relationships with clients
  • Reaching of milestones and final / ongoing outcomes
  • Building and maintaining existing and long-term partnerships
     

PMG Research has been shortlisted as Best Clinical Trial Site or Network for demonstrating success according to the following criterial:

  • Matching clinical development needs through a complete programmatic assessment
  • Supportive of multiple and diverse clinical phase and outcomes trials for vaccines
  • Methods of performance improvement or introduction of new services
  • Rapid enrolment across a variety of vaccine ranges and outstanding study subject retention
  • Reaching of milestones and final / ongoing outcomes / trials

Click here to cast your vote in the 2016 VIE Awards.

The award winners will be announced at the 9th ViE Awards Ceremony & Gala Dinner in Washington on March 29th. is

About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 38 countries and has approximately 11,900 employees.

Further information is available at www.iconplc.com/vaccines

ICON Media Contact

Pippa Chester
Weber Shandwick
+44 (0) 207 067 0190
[email protected]

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.